Overview

A 36-marker female tumor susceptibility assessment evaluates a broad set of variants associated with inherited cancer risk in women. Its strength is population stratification: by aggregating many susceptibility signals it can separate a routinely elevated background from a genuinely high-risk profile that warrants closer surveillance.

How It Works

The assessment scores each of the 36 markers and combines them into a risk picture rather than reporting isolated mutations. Population relevance comes from comparing an individual's pattern against reference cohorts of affected and unaffected women. This polygenic style of evaluation is different from single-gene testing, because it weighs many small-effect variants together. B2B buyers should ask how the scoring model was built and on which population it was trained.

Indications

The assessment is aimed at women seeking a structured hereditary-risk picture, especially those with a suggestive but non-diagnostic family history. It supports counselling and surveillance planning rather than treatment. The appropriate channel is clinics and screening programmes that can act on a graded risk result, since a mid-range score needs context that a raw number alone cannot provide.

Dosage & Administration

No dosage. The meaningful inputs are the marker list, the reference population, and the reporting bands. A procurement specification should fix the risk thresholds that trigger a recommendation and the counselling content bundled with each result. Define upfront how borderline scores are handled so that downstream clinicians interpret them consistently.

Storage & Sourcing

Sample stability and data governance dominate the practical risks. Kits require validated stabilisation and a tracked transport chain; the laboratory needs accredited storage of extracted material. Because a 36-marker result is inherently identifiable, B2B programmes must include a long-term privacy and re-consent policy, and the buyer should confirm the model's training data is appropriate for the populations they serve.

FAQ

Q: How is a 36-marker assessment different from single-gene testing?

It combines many small-effect variants into a graded risk score instead of flagging one causal mutation. This suits population screening but depends heavily on the reference cohort used.

Q: Which women benefit most?

Those with a family hint of hereditary cancer but no single clear syndrome, and programmes wanting to prioritise surveillance. A strong family history of one gene still warrants targeted testing.

Q: Can the score guide treatment directly?

No. It informs risk awareness and surveillance intensity. Any clinical action should follow professional interpretation within a counselling pathway.

Q: Why does the reference population matter?

Risk scores are population-specific. A model trained on one ethnicity may misclassify another, so buyers must confirm the training cohort matches their patient base.